PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR

Podobné jednotky

• Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
  Autor: Isla D, a další
  Vydáno: (2016-12-01)
• Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
  Autor: Debby D Wang, a další
  Vydáno: (2015-01-01)
• EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
  Autor: Florent Baty, a další
  Vydáno: (2013-01-01)
• Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non–Small Cell Lung Cancer Cells
  Autor: Yasemin Saygideğer-Kont, a další
  Vydáno: (2016-02-01)
• Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis
  Autor: Rodrigo Motta-Guerrero, a další
  Vydáno: (2024-01-01)